Jiyan Biotech debuts with the One - Stop Solution for Fatty Liver Organoid Modeling at the Annual Meeting of the Liver Disease New Drug Alliance-Suzhou Jiyan Biotech Co., Ltd.

Jiyan Biotech debuts with the One - Stop Solution for Fatty Liver Organoid Modeling at the Annual Meeting of the Liver Disease New Drug Alliance

Jiyan Biotech makes an appearance at the Annual Conference of Liver Disease New Drugs

From December 13th to 14th, 2024, the 2024 Annual Meeting of the Liver Disease New Drug Alliance and the Symposium on Metabolic - Associated Fatty Liver Disease, co - hosted by the Liver Disease New Drug Alliance and YaoTimes, were successfully held in Shanghai. The event gathered over 30 liver disease experts and industry leaders from industry, academia, research, and investment. Centering on the theme "Seize the Opportunities of the Times and Conquer Stubborn Liver Diseases!", they delivered wonderful presentations.

Metabolic - Associated Fatty Liver Disease（MAFLD）

Fatty liver disease, or fatty liver for short, is marked by excessive fat accumulation and steatosis in hepatocytes. When a large quantity of fat is generated and cannot be promptly transported out of the liver, it accumulates in hepatocytes. Over time, fatty liver ensues.

Metabolic - associated fatty liver disease (MAFLD) is the most common chronic liver ailment clinically, affecting over a quarter of the global population. In 2020, the International Fatty Liver Expert Group recommended renaming non - alcoholic fatty liver disease (NAFLD) as MAFLD. MAFLD can progress to metabolic - associated steatohepatitis (MASH), leading to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), severely endangering human health.

In recent years, MAFLD incidence has been rising steadily in China. Epidemiological surveys in Shanghai, Beijing, etc., as per the "Guidelines for the Prevention and Treatment of Metabolic - Associated (Non - Alcoholic) Fatty Liver Disease (2024 Edition)", show that the prevalence of MAFLD diagnosed by B - ultrasound in the general adult population increased from 15% to over 31% in a decade. Before the age of 50 - 55, the prevalence is higher in men; afterward, it grows faster in women and even exceeds that in men. MAFLD has become the leading cause of chronic liver disease in China, overtaking viral hepatitis and alcoholic liver disease.

Currently, there are no effective treatments or drugs to halt or reverse fatty liver. As the disease progresses, the risk of irreversible liver damage and the need for liver transplantation escalate significantly. Moreover, fatty liver patients have a higher risk of developing liver cancer.

Regarding research models for metabolic disorders, mice, as animal models, have metabolic mechanisms vastly different from those of humans, rendering them unsuitable as representative models for human metabolic diseases. Thus, due to a lack of proper research models, the study of fatty liver prevention and treatment methods faces formidable challenges in disease research and new drug development.

On February 23, 2023, the Hans Clevers team published a paper titled "Engineered human hepatocyte organoids enable CRISPR - based target discovery and drug screening for steatosis" in Nature Biotechnology. The study established a novel human fatty - liver organoid model and used it to elucidate drug responses. These organoid models and screening platforms will aid in testing and developing new drugs for fatty liver treatment and enhance our understanding of disease biology.

640 (2).png

Applications of Organoids in Liver Disease Modeling and Drug Evaluation

Organoids are three - dimensional (3D) cell cultures that possess the key structural and functional characteristics of specific organs. Compared with human cell lines and animal models, organoids replicate the three - dimensional structure of primary tissues. They are more closely aligned with the structural and functional properties of in - vivo tissues, capable of mimicking the structural and functional features of organs in the body. As a result, they are widely utilized in disease modeling, drug screening, and drug safety assessment.

Primary hepatocytes have now emerged as one of the primary sources for liver organoids. A growing body of research indicates that mature hepatocytes retain stem - like potential and proliferative capacity within specific environments. The high genetic stability of tissue - derived liver organoids, along with their strong resemblance to the actual organ, positions them as a novel option for in - vitro drug testing. Consequently, tissue - derived organoids continue to hold significant research value and exhibit broad prospects for clinical applications.

Jiyan Biotech's New Product Launch

Fatty Liver Cell Model Building Kit

The construction of MAFLD organoid models mainly involves adding Stimulant I to induce fatty degeneration in hepatocytes. For AFLD (Alcoholic Fatty Liver Disease) organoid models, Stimulant II is added to induce fatty degeneration in hepatocytes. This kit is applicable to 2D and 3D cells of human, murine, and simian origin.

//cdn.myxypt.com/30d9825b/25/01/93b7d780b3a52bdcf82c26810a36eecf5312c672.png

Oil Red O Staining Kit

The Oil Red O Staining Kit is a reagent kit that uses Oil Red O dye to specifically stain neutral lipids such as triglycerides in cells or tissues red or orange - yellow. This kit is applicable to samples such as cells, organoids, frozen tissue sections, bone marrow smears, or blood smears, but is not suitable for paraffin - embedded tissue sections.

//cdn.myxypt.com/30d9825b/25/01/eff5816c8ac684bed4b3a53242ecd119e26f2c3e.png

Nile Red Fluorescence Detection Kit

Nile Red Fluorescence Detection Reagent (Nile Red), also known as Nile blue oxazone, has a molecular weight of 318.37. Nile Red is a hydrophobic fluorescent dye that can be used for lipid staining. Nile Red has poor solubility in water and weak fluorescence. In a hydrophobic environment, its color emission ranges from dark red to intense yellow. When performing fluorescence staining of lipids, yellow excitation light between 450nm - 500nm is recommended, and its emission light is greater than 528nm. This kit is suitable for fluorescence detection instruments such as fluorescence microscopes and flow cytometers.

//cdn.myxypt.com/30d9825b/25/01/b6cf4c79c2202fd84074c7de88e65b900590594d.png

Technical Service: Research on Fatty Liver Organoid Modeling

In addition to zero - foundation, ready - to - use reagent kits, we also offer customized technical services and solutions. Contact us at +86 139 1378 9040 (WeChat available).